Anixa Biosciences, Inc. cash flow to debt ratio of -3.52K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Anixa Biosciences, Inc.'s free cash flow has increased -2.21% from $-7.33M last year to $-7.17M, signaling increasing performance

Anixa Biosciences, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Anixa Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

Anixa Biosciences, Inc. has a net cash position, so leverage is healthy.

Anixa Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Anixa Biosciences, Inc. has insufficient data to evaluate this check.

Anixa Biosciences, Inc.'s short-term assets of $15.89M exceed its short-term liabilities of $1.97M

Anixa Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Anixa Biosciences, Inc.'s return on equity of -65.73%, is lower than 15.00%, indicating bad performance

Anixa Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Anixa Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Anixa Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Anixa Biosciences, Inc. has negative free cash flow, indicating cash burn

Anixa Biosciences, Inc.'s yearly earnings has increased -12.96% since last year from $-12.55M to $-10.93M, signaling increasing performance

Anixa Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -79.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Anixa Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Anixa Biosciences, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Anixa Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Anixa Biosciences, Inc. has insufficient data to evaluate this check.

Anixa Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Anixa Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Anixa Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Anixa Biosciences, Inc. has insufficient data to evaluate this check.

Anixa Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Anixa Biosciences, Inc. has a price-to-book ratio of 8.26x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Anixa Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue